Please login to the form below

Not currently logged in
Email:
Password:

Xofigo

This page shows the latest Xofigo news and features for those working in and with pharma, biotech and healthcare.

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

CHMP turns down BMS’ Opdivo/Yervoy for kidney cancer

Finally, the CHMP said after a review of the clinical data for Bayer’s metastatic prostate cancer therapy Xofigo (radium-223 dichloride) that it was recommending restricting its use to patients ... It’s a blow for Bayer, which has billed Xofigo as

Latest news

  • Pharma sales help Bayer escape the worst from a bumpy 2017 Pharma sales help Bayer escape the worst from a bumpy 2017

    The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

  • Xarelto and Eylea continue to dominate Bayer's pharma sales Xarelto and Eylea continue to dominate Bayer's pharma sales

    The two products accounted for around 28% of Bayer's total pharma sales last year and are regarded as key growth products for the firm, along with its cancer drugs Xofigo ... Last year Xofigo (radium-223 dichloride) brought in 331m (up 29%) and Adempas

  • Xarelto leads the charge at Bayer Xarelto leads the charge at Bayer

    There were also gains for Eylea (aflibercept) for age-related macular degeneration (AMD) as well as prostate cancer drug Xofigo (radium Ra 223 dichloride) and Adempas (riociguat) for pulmonary artery hypertension.

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    Japanese approvals for GSK, AZ and Bayer. MHLW gives Nucala, Tagrisso and Xofigo the green light. ... Bayer has said it expects 50%-plus sales growth for Xofigo this year.

More from news
Approximately 10 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta).

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

  • Pharma deals during November 2013 Pharma deals during November 2013

    This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under joint development since 2009. ... Peak sales for Xofigo are expected to reach $1.5bn plus further upside from other indications in development.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics